Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Vext Science's Enterprise Value for the quarter that ended in Jun. 2026 was €60.05 Mil.
Vext Science's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science EV-to-EBIT Related Terms
Vext Science EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Vext Science's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vext Science's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vext Science EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vext Science's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Vext Science's EV-to-EBIT falls into.
Vext Science's current Enterprise Value is €68.04 Mil.
Vext Science's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.95 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vext Science (FRA:VV5) has a EV-to-EBIT of -9.79 as of Aug. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vext Science and its competitors. According to the industry distribution chart, Vext Science ranks #999999 out of 691 companies in the Drug Manufacturers industry.
Is Vext Science's EV-to-EBIT too high?
Vext Science's current EV-to-EBIT is -9.79. Based on the distribution chart, Vext Science ranks #999999 out of 691 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vext Science has a GF Score™ of 55/100, reflecting its overall financial health beyond just this single metric.
How does Vext Science's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vext Science ranks #999999 out of 691 companies for EV-to-EBIT. This places Vext Science in the lower half of its industry. The industry median EV-to-EBIT is 15.77. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.77, based on 691 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Vext Science and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.77 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vext Science's current EV-to-EBIT is -9.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vext Science stock overvalued right now?
Vext Science (FRA:VV5) has a current EV-to-EBIT of -9.79. The stock's GF Value™ is €1.11, compared to a current price of €0.17 — trading 84.7% below its estimated fair value. The current EV-to-EBIT is -9.79. Vext Science's overall GF Score™ is 55/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Vext Science (FRA:VV5), the current EV-to-EBIT is -9.79 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vext Science (FRA:VV5) Overvalued in 2026?
Based on GuruFocus' analysis, Vext Science stock appears to be undervalued.
The current stock price of €0.17 is trading 84.7% below its estimated GF Value™ of €1.11.
Key valuation signals for FRA:VV5:
EV-to-EBIT: -9.79
GF Value™: €1.11 vs. price of €0.17 (84.7% below fair value)
No single metric tells the full story. See the FRA:VV5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vext Science Inc engages in the full spectrum of the cannabis product lifecycle, from development and manufacturing to distribution. Its brands include Herbal Wellness, Appalachian Pharm, Revibe, Prism, Vapen, and Firebrand. In Arizona and Ohio, the dispensaries operate under the Herbal Wellness Center brand, while in Ohio the cultivation and manufacturing operations are licensed and branded as Appalachian Pharms Cultivation and Appalachian Pharm Processing. The Company operates through a single operating segment engaged in the cultivation, manufacturing, distribution, and sale of cannabis within the United States. All revenues are generated in the United States.
55GF Score
Get the complete analysis for FRA:VV5
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:VV5 has been successfully added to your 
